EDAP Received Significant Visibility for Ablatherm-HIFU at American Urological Association Annual Meeting
2010年6月9日 - 2:22AM
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic
ultrasound, today announced that it was a major participant at the
American Urological Association (AUA) 2010 Annual Meeting, held May
29 – June 3, 2010 in San Francisco. As part of the scientific
program, four abstracts were presented that outlined the long-term
positive European experience utilizing EDAP's Ablatherm-HIFU
treatment for localized prostate cancer as summarized below.
Marc Oczachowski, EDAP's Chief Executive Officer, commented, "We
were pleased with the strong reception that our technology and
products received at AUA 2010. This prestigious meeting
attracts a broad spectrum of urologists from both the U.S. and
around the globe. The four abstracts that were presented
represented the largest studies ever conducted among HIFU devices.
We are proud of the positive reception that these studies
received and expect that awareness will continue to grow
globally. These results confirm that this lifestyle preserving
treatment for localized prostate cancer is on par with other more
invasive treatment options such as surgery."
- "Outcomes of HIFU for Prostate Cancer in 880 Consecutive
Patients," presented by Dr. Crouzet, Lyon, France. This is the
largest multi-center study ever presented of patients, who have
undergone HIFU as a primary therapy for prostate cancer, and
included patients treated successfully for more than 10 years ago.
This study was facilitated by the @-Registry (also called the
"Ablatherm Treatment" Registry), the largest database of
Ablatherm-HIFU patients ever compiled. The results showed success
of HIFU on par with the traditional therapies of surgery and
radiation therapy.
- "HIFU Following Failed Radiation Therapy: Biochemical Survival
of Ablatherm Registry," presented by Dr. John Ward, MD Anderson,
Houston Texas. This is the largest patient series ever presented of
patients who have undergone HIFU as a curative treatment after
failed radiation therapy. Collected with the @-Registry, data from
434 men demonstrated no biochemical evidence of prostate cancer in
over half of men four years after treatment. The paper concluded
that the results were encouraging and showed the ability to return
men to disease free status with HIFU after failed radiation
therapy.
- "Correlation of Different PSA-Nadir Cut Offs and Biochemical
Failure After High Intensity Focused Ultrasound (HIFU) of Prostate
Cancer Based on the Stuttgart Failure Criteria," presented by Dr.
Roman Ganzer, Regensburg University, Regensburg, Germany. This
study confirmed earlier observations that patients get a very early
indication of the successfulness of their treatment. The study
stated this is important because if a treatment is not successful,
early confirmation of this allows for early action to retreat. This
is not possible with radiation therapy, which requires 18-24 months
post treatment to determine success.
- "Hormone Resistant Prostate Cancer Treated by Robotic High
Intensity Ultrasound," presented by Christian Chaussy, Harlaching
Hospital, Munich, Germany. Hormone therapy is used to treat
metastatic prostate cancer. When the disease becomes resistant to
hormones, therapy becomes palliative and life expectancy rapidly
shortens. In this study, 55 men with hormone resistant prostate
cancer were treated with HIFU and followed up to 9.5 years. The
study concluded that adjuvant HIFU achieved a longer survival with
good quality of life.
Based on his strong experience at the largest European
Ablatherm-HIFU center, Harlaching Hospital in Munich, Germany, Pr.
Christian Chaussy presented an update on HIFU technology for the
treatment of localized prostate cancer during a special program
dedicated to the Engineering and Urology Society, which promotes
the development and application of new technology in urology
through the collaborative efforts of engineers, physicists, and
urologists. The presentation focused on the engineering community,
which is involved in the endorsement and selection of innovative
technologies such as HIFU.
Dr. John Rewcastle, EDAP TMS Medical Director, concluded, "These
studies, which together report the outcomes of over 1,350 men who
have undergone HIFU, underscore the versatility, dependability and
success of HIFU as a prostate cancer treatment. Specifically, the
large primary and salvage series substantiate earlier observations
of HIFU's efficacy but now on a much larger scale. The hormone
resistant treatment is novel and may prove to be a valuable
treatment for a population of men with limited options."
About EDAP TMS SA
EDAP TMS SA develops and markets Ablatherm, the most advanced
and clinically proven choice for high-intensity focused ultrasound
(HIFU) treatment of localized prostate cancer. HIFU treatment is
shown to be a minimally invasive and effective treatment option
with a low occurrence of side effects. Ablatherm-HIFU is generally
recommended for patients with localized prostate cancer (stages
T1-T2) who are not candidates for surgery or who prefer an
alternative option, or for patients who failed radiotherapy
treatment. Approved in Europe as a treatment for prostate cancer,
Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently
undergoing evaluation in a multicenter U.S. Phase II/III clinical
trial under an Investigational Device Exemption granted by the FDA,
the ENLIGHT U.S. clinical study. The Company also is developing
this technology for the potential treatment of certain other types
of tumors. EDAP TMS SA also produces and commercializes medical
equipment for treatment of urinary tract stones using
extra-corporeal shockwave lithotripsy (ESWL). For more information
on the Company, please visit http://www.edap-tms.com,
http://www.hifu-planet.com.
CONTACT: EDAP TMS SA
Investor Relations / Legal Affairs
Blandine Confort
+33 4 72 15 31 72
bconfort@edap-tms.com
The Ruth Group
Investors:
Stephanie Carrington
646-536-7017
scarrington@theruthgroup.com
EDAP TMS (NASDAQ:EDAP)
過去 株価チャート
から 9 2024 まで 10 2024
EDAP TMS (NASDAQ:EDAP)
過去 株価チャート
から 10 2023 まで 10 2024